CL2008001633A1 - Compuestos derivados de pirrolidin-3-carboxamida; composición farmacéutica; y uso comominhibidores de erk para el tratamiento del cancer. - Google Patents
Compuestos derivados de pirrolidin-3-carboxamida; composición farmacéutica; y uso comominhibidores de erk para el tratamiento del cancer.Info
- Publication number
- CL2008001633A1 CL2008001633A1 CL2008001633A CL2008001633A CL2008001633A1 CL 2008001633 A1 CL2008001633 A1 CL 2008001633A1 CL 2008001633 A CL2008001633 A CL 2008001633A CL 2008001633 A CL2008001633 A CL 2008001633A CL 2008001633 A1 CL2008001633 A1 CL 2008001633A1
- Authority
- CL
- Chile
- Prior art keywords
- pyrrolidin
- carboxamide
- pharmaceutical composition
- cancer
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
Abstract
Compuestos derivados de pirrolidin-3-carboxamida; composición farmacéutica; y uso en el tratamiento del cáncer.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/810,282 US8546404B2 (en) | 2005-12-13 | 2007-06-05 | Compounds that are ERK inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2008001633A1 true CL2008001633A1 (es) | 2008-12-12 |
Family
ID=39737670
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2008001633A CL2008001633A1 (es) | 2007-06-05 | 2008-06-04 | Compuestos derivados de pirrolidin-3-carboxamida; composición farmacéutica; y uso comominhibidores de erk para el tratamiento del cancer. |
Country Status (20)
Country | Link |
---|---|
EP (1) | EP2155722B1 (es) |
JP (1) | JP2010529122A (es) |
KR (1) | KR20100025553A (es) |
CN (1) | CN101815711A (es) |
AR (1) | AR068046A1 (es) |
AU (1) | AU2008262412A1 (es) |
BR (1) | BRPI0812450A2 (es) |
CA (1) | CA2694860A1 (es) |
CL (1) | CL2008001633A1 (es) |
CO (1) | CO6251261A2 (es) |
EC (1) | ECSP099781A (es) |
IL (1) | IL202317A0 (es) |
MX (1) | MX2009013333A (es) |
MY (1) | MY148609A (es) |
NZ (1) | NZ581698A (es) |
PE (1) | PE20090326A1 (es) |
RU (1) | RU2475484C2 (es) |
TW (1) | TW200911262A (es) |
WO (1) | WO2008153858A1 (es) |
ZA (1) | ZA200908477B (es) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8546404B2 (en) | 2005-12-13 | 2013-10-01 | Merck Sharp & Dohme | Compounds that are ERK inhibitors |
CN102015693B (zh) | 2008-02-21 | 2014-10-29 | 默沙东公司 | 作为erk抑制剂的化合物 |
WO2010021978A2 (en) * | 2008-08-19 | 2010-02-25 | Schering Corporation | Il-8 biomarker |
US9229008B2 (en) | 2008-08-19 | 2016-01-05 | Merck Sharp & Dohme Corp. | IL-8 level as a determinant of responsivity of a cancer to treatment |
JO2860B1 (en) | 2009-05-07 | 2015-03-15 | ايلي ليلي اند كومباني | Phenylendazolyl compounds |
WO2011163330A1 (en) | 2010-06-24 | 2011-12-29 | Merck Sharp & Dohme Corp. | Novel heterocyclic compounds as erk inhibitors |
WO2012015932A2 (en) * | 2010-07-27 | 2012-02-02 | Protexer, Inc. | Shoe cover removal apparatus |
WO2012030685A2 (en) | 2010-09-01 | 2012-03-08 | Schering Corporation | Indazole derivatives useful as erk inhibitors |
US9351965B2 (en) | 2010-12-21 | 2016-05-31 | Merck Sharp & Dohme Corp. | Indazole derivatives useful as ERK inhibitors |
EP2487159A1 (en) | 2011-02-11 | 2012-08-15 | MSD Oss B.V. | RorgammaT inhibitors |
US20150141470A1 (en) | 2012-05-08 | 2015-05-21 | The Broad Institute, Inc. | Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy |
CN103450163B (zh) * | 2012-05-29 | 2017-06-23 | 中国医学科学院药物研究所 | 吲唑类化合物、其制备方法及其药物用途 |
WO2014026329A1 (en) | 2012-08-15 | 2014-02-20 | Merck Sharp & Dohme Corp. | N-alkylated indole and indazole compounds as rorgammat inhibitors and uses thereof |
WO2014026327A1 (en) | 2012-08-15 | 2014-02-20 | Merck Sharp & Dohme Corp. | 4-heteroaryl substituted benzoic acid compounds as rorgammat inhibitors and uses thereof |
MX2015003535A (es) | 2012-09-19 | 2015-07-14 | Novartis Ag | Dihidro-pirrolidino-pirimidinas como inhibidoras de cinasa. |
SG11201602572YA (en) | 2013-10-03 | 2016-04-28 | Kura Oncology Inc | Inhibitors of erk and methods of use |
TN2016000081A1 (en) | 2013-11-01 | 2017-07-05 | Novartis Ag | Aminoheteroaryl benzamides as kinase inhibitors |
CA2934669C (en) * | 2013-12-20 | 2022-10-04 | Biomed Valley Discoveries, Inc. | Cancer treatment using combinations of erk and raf inhibitors |
JP6678584B2 (ja) * | 2013-12-20 | 2020-04-22 | バイオメッド バレー ディスカバリーズ,インコーポレイティド | Cdk阻害剤およびerk阻害剤の組み合わせを使用するがん処置 |
WO2015095838A2 (en) * | 2013-12-20 | 2015-06-25 | Biomed Valley Discoveries, Inc. | Cancer treatments using combinations of mek type i and erk inhibitors |
AU2014368912B2 (en) * | 2013-12-20 | 2020-04-30 | Biomed Valley Discoveries, Inc. | Cancer treatments using combinations of type 2 MEK and ERK inhibitors |
WO2016095088A1 (en) | 2014-12-15 | 2016-06-23 | Merck Sharp & Dohme Corp. | Erk inhibitors |
WO2016095089A1 (en) | 2014-12-15 | 2016-06-23 | Merck Sharp & Dohme Corp. | Erk inhibitors |
EP3256450B1 (en) | 2015-02-11 | 2020-12-02 | Merck Sharp & Dohme Corp. | Substituted pyrazole compounds as ror-gamma-t inhibitors and uses thereof |
GB201511382D0 (en) | 2015-06-29 | 2015-08-12 | Imp Innovations Ltd | Novel compounds and their use in therapy |
AU2016344111A1 (en) | 2015-10-27 | 2018-05-10 | Merck Sharp & Dohme Corp. | Substituted bicyclic pyrazole compounds as RORgammaT inhibitors and uses thereof |
EP3368535B1 (en) | 2015-10-27 | 2020-12-02 | Merck Sharp & Dohme Corp. | Heteroaryl substituted benzoic acids as rorgammat inhibitors and uses thereof |
CA3002850A1 (en) | 2015-10-27 | 2017-05-04 | Merck Sharp & Dohme Corp. | Substituted indazole compounds as rorgammat inhibitors and uses thereof |
CA3090842A1 (en) | 2018-03-12 | 2019-09-19 | Abbvie Inc. | Inhibitors of tyrosine kinase 2 mediated signaling |
EP3725777A1 (en) * | 2019-04-17 | 2020-10-21 | Rottapharm Biotech S.r.l. | Benzo- and pyrido-pyrazoles as protein kinase inhibitors |
CN114605329B (zh) * | 2022-03-28 | 2024-01-26 | 河南中医药大学 | 取代的吲唑甲酰胺或取代的氮杂吲唑甲酰胺类flt3抑制剂及其用途 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9213077D0 (en) | 1992-06-19 | 1992-08-05 | Erba Carlo Spa | Polymerbound taxol derivatives |
TW349948B (en) | 1995-10-31 | 1999-01-11 | Janssen Pharmaceutica Nv | Farnesyl transferase inhibiting 2-quinolone derivatives |
US5874442A (en) | 1995-12-22 | 1999-02-23 | Schering-Plough Corporation | Tricyclic amides useful for inhibition of G-protein function and for treatment of proliferative disease |
US6011029A (en) | 1996-02-26 | 2000-01-04 | Bristol-Myers Squibb Company | Inhibitors of farnesyl protein transferase |
US6632455B2 (en) | 1997-12-22 | 2003-10-14 | Schering Corporation | Molecular dispersion composition with enhanced bioavailability |
US6130235A (en) * | 1998-05-22 | 2000-10-10 | Scios Inc. | Compounds and methods to treat cardiac failure and other disorders |
MY130778A (en) * | 2001-02-09 | 2007-07-31 | Vertex Pharma | Heterocyclic inhibitiors of erk2 and uses thereof |
WO2002088090A2 (en) * | 2001-04-27 | 2002-11-07 | Vertex Pharmaceuticals Incorporated | Pyrazole derived kinase inhibitors |
NZ551582A (en) * | 2004-05-14 | 2011-01-28 | Vertex Pharma | Pyrrole compounds as inhibitors of ERK protein kinase, synthesis thereof and intermediates thereto |
EP1966151B1 (en) * | 2005-12-13 | 2011-10-05 | Schering Corporation | Polycyclic indazole derivatives that are erk inhibitors |
-
2008
- 2008-06-04 CN CN200880100968A patent/CN101815711A/zh active Pending
- 2008-06-04 BR BRPI0812450A patent/BRPI0812450A2/pt not_active IP Right Cessation
- 2008-06-04 AU AU2008262412A patent/AU2008262412A1/en not_active Abandoned
- 2008-06-04 KR KR1020097027487A patent/KR20100025553A/ko not_active Application Discontinuation
- 2008-06-04 WO PCT/US2008/006979 patent/WO2008153858A1/en active Application Filing
- 2008-06-04 MX MX2009013333A patent/MX2009013333A/es active IP Right Grant
- 2008-06-04 TW TW097120755A patent/TW200911262A/zh unknown
- 2008-06-04 CA CA2694860A patent/CA2694860A1/en not_active Abandoned
- 2008-06-04 EP EP08768067.4A patent/EP2155722B1/en active Active
- 2008-06-04 AR ARP080102366A patent/AR068046A1/es unknown
- 2008-06-04 NZ NZ581698A patent/NZ581698A/xx not_active IP Right Cessation
- 2008-06-04 RU RU2009148867/04A patent/RU2475484C2/ru not_active IP Right Cessation
- 2008-06-04 MY MYPI20095228A patent/MY148609A/en unknown
- 2008-06-04 PE PE2008000942A patent/PE20090326A1/es not_active Application Discontinuation
- 2008-06-04 CL CL2008001633A patent/CL2008001633A1/es unknown
- 2008-06-04 JP JP2010511172A patent/JP2010529122A/ja not_active Ceased
-
2009
- 2009-11-24 IL IL202317A patent/IL202317A0/en unknown
- 2009-11-30 ZA ZA2009/08477A patent/ZA200908477B/en unknown
- 2009-12-03 EC EC2009009781A patent/ECSP099781A/es unknown
- 2009-12-04 CO CO09139231A patent/CO6251261A2/es active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
CN101815711A (zh) | 2010-08-25 |
EP2155722A1 (en) | 2010-02-24 |
MY148609A (en) | 2013-05-15 |
ECSP099781A (es) | 2010-01-29 |
AR068046A1 (es) | 2009-11-04 |
CA2694860A1 (en) | 2008-12-18 |
NZ581698A (en) | 2012-09-28 |
WO2008153858A1 (en) | 2008-12-18 |
JP2010529122A (ja) | 2010-08-26 |
MX2009013333A (es) | 2010-01-18 |
PE20090326A1 (es) | 2009-04-04 |
AU2008262412A2 (en) | 2010-01-07 |
AU2008262412A1 (en) | 2008-12-18 |
CO6251261A2 (es) | 2011-02-21 |
IL202317A0 (en) | 2010-06-30 |
TW200911262A (en) | 2009-03-16 |
KR20100025553A (ko) | 2010-03-09 |
RU2475484C2 (ru) | 2013-02-20 |
BRPI0812450A2 (pt) | 2019-09-24 |
RU2009148867A (ru) | 2011-07-20 |
EP2155722B1 (en) | 2013-08-14 |
ZA200908477B (en) | 2012-05-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2008001633A1 (es) | Compuestos derivados de pirrolidin-3-carboxamida; composición farmacéutica; y uso comominhibidores de erk para el tratamiento del cancer. | |
CL2009000483A1 (es) | Compuestos derivados de n-(piridin-3-il)-1,3-tiazol-5-amino-4-carboxamida, inhibidores de cinasa pim; composicion farmaceutica; y uso para el tratamiento del cancer. | |
CL2012002189A1 (es) | Compuestos derivados de pirrolidina-2-carboxamidas sustituidas; inhibidores de la interaccion mdm2-p53; composicion farmaceutica; y su uso para el tratamiento del cancer, en particular de tumores solidos. | |
CL2015000829A1 (es) | Inhibidores de histona desmetilasas | |
CL2008001540A1 (es) | Compuestos derivados de pirrolopiridinas y pirazolopiridinas; composicion farmaceutica; y uso en el tratamiento del cancer. | |
CL2011000191A1 (es) | Compuestos derivados de pirimidina fusionada sustituida,inhibidores de mtor; composicion farmaceutica que lo comprende; y uso en el tratamiento del cancer. | |
CL2016001231A1 (es) | Compuestos de inhibidor de autotaxina | |
CL2011000454A1 (es) | Compuestos derivados de picolinamida, inhibidores de quinasa pim, asociada a tumorigenesis; composicion farmaceutica que los comprende; y su uso en el tratamiento del cancer. | |
CL2012003415A1 (es) | Compuestos derivados de 2-oxo-piperidina y 1,1-dioxido-tiazina, inhibidores de mdm2; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer . | |
CL2008002369A1 (es) | Compuestos derivados de piridin-3-il-oxipiridin-2-il-amino, inhibidores de alk5; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento del cancer. | |
CL2008002097A1 (es) | Compuestos derivados de heterociclos condensados sustituidos, inhibidores de cinasa de fosfatidil-inositol-3; composicion farmaceutica; y uso en el tratamiento del cancer. | |
CL2012001405A1 (es) | Compuestos derivados de espiroindolinona-pirrolidinas; proceso de obtención; composicion farmaceutica; y uso en el tratamiento o profilaxis del cancer. | |
CL2007001435A1 (es) | Compuestos derivados de fenilalanina; proceso de prepatacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto como inhibidores de integrina para el tratamiento del cancer. | |
CL2007002316A1 (es) | Compuestos derivados de pirimidina, inhibidores de pi3k; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en enfermedades proliferativas como cancer. | |
CL2008001373A1 (es) | Compuestos derivados de fenilamino-benceno sustituidos; metodo de preparacion; composicion farmaceutica; kit farmceuticos; y uso de dichos compuestos en el tratamiento del cancer. | |
CL2008001076A1 (es) | Compuestos derivados de sulfonamida; composicion farmaceutica; y uso en el tratamiento del cancer. | |
CL2007003774A1 (es) | Compuestos derivados de quinazolina sustituidos, inhibidores de quinasa; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, aterosclerosis y artritis. | |
CL2014002873A1 (es) | Compuestos derivados de pirimidin-amina o triazin-amina, inhibidores de adn-pk; composicion farmaceutica; y su uso para el tratamiento del cancer. | |
CL2007003226A1 (es) | Compuestos derivados de piridinona; composicion farmaceutica; y uso para tratar el cancer. | |
CL2008001234A1 (es) | Compuestos derivados de heterociclos nitrogenados, inhibidores de las proteinas de apoptosis; y uso en el tratamiento del cancer. | |
CR20140544A (es) | Compuestos para inhibir la progresión mitotica | |
CL2009000426A1 (es) | Compuestos derivados de carbociclil/heterociclil-piridin-2-il-urea, inhibidores de topoisomerasa iv bacteriana; composicion farmaceutica; y su uso para el tratamiento de infecciones bacterianas | |
CL2012000772A1 (es) | Compuestos derivados de hetorociclos carboxamidicos sustituidos, antagonista ar; composición farmacéutica que los comprende; y uso en el tratamiento del cáncer de próstata. | |
ECSP078013A (es) | Inhibidores heterocíclicos de mek y métodos de uso de ellos | |
CL2013000018A1 (es) | Compuestos derivados de indolizina , su procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento del cancer, entre otros. |